{"id":"abequolixron","rwe":[],"tags":[],"phase":"discontinued","safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[],"contraindications":[],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[]},"status":"discontinued","trials":["NCT05911308"],"aliases":[],"patents":[],"pricing":[],"offLabel":[],"timeline":[{"date":"2024","type":"negative","milestone":"Phase 1 Initiated","description":"Abequolixron (RGX-104) and Durvalumab in Lung Cancer — Non-Small Cell Lung Cancer. Trial terminated early."}],"aiSummary":"Abequolixron is a drug being investigated in lung cancer treatment. It is part of a Phase 1 clinical trial evaluating its use in combination with Durvalumab. The trial included a single patient.","brandName":"ABEQUOLIXRON","companyId":"unknown","ecosystem":[],"mechanism":{"target":"","novelty":"","modality":"Small molecule","drugClass":"","explanation":"The provided text does not contain information about the mechanism of action of Abequolixron. Therefore, a plain English explanation cannot be generated from the source data.","oneSentence":"Abequolixron is being studied with Durvalumab in a small lung cancer clinical trial.","technicalDetail":"Abequolixron (RGX-104) is being studied in combination with Durvalumab in lung cancer. The clinical trial is a Phase 1 trial with a sample size of one patient (n=1). No further technical details are provided in the source text."},"commercial":null,"references":[],"biosimilars":[],"companyName":"","competitors":[],"dataSources":[{"url":"https://clinicaltrials.gov","name":"ClinicalTrials.gov","fields":["trialDetails","trials"],"retrievedDate":"2026-04-07"}],"genericName":"ABEQUOLIXRON","indications":{"approved":[],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT05911308","phase":"Phase 1","title":"A Pilot Window of Opportunity Study Evaluating Durvalumab (MEDI4736) in Combination With Platinum Doublet Chemotherapy Followed by Evaluation of Durvalumab (MEDI4736) in Combination With Platinum Doub","status":"TERMINATED","sponsor":"UNC Lineberger Comprehensive Cancer Center","isPivotal":false,"enrollment":1,"indication":"Non-Small Cell Lung Cancer","completionDate":"2025-02-27"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"icon":"","route":"","frequency":"","formulation":""},"formularyStatus":[],"apiManufacturers":[],"developmentCodes":[],"ownershipHistory":[],"therapeuticAreas":["Oncology"],"biosimilarFilings":[],"firstApprovalDate":"","companionDiagnostics":[],"firstApprovalCountry":null,"genericManufacturerList":[],"modality":"Small molecule","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}